Home

Gilead Sciences (GILD)

106.75
-3.48 (-3.15%)

Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close110.23
Open109.69
Bid106.73
Ask106.76
Day's Range105.80 - 109.72
52 Week Range62.07 - 119.96
Volume6,127,650
Market Cap133.85B
PE Ratio (TTM)288.52
EPS (TTM)0.4
Dividend & Yield3.080 (2.89%)
1 Month Average Volume9,662,983

News & Press Releases

Which S&P500 stocks are gapping on Wednesday?chartmill.com
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.
Via Chartmill · March 19, 2025
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Fundinginvestors.com
HIV prevention is a staple in Gilead Sciences' wheelhouse.
Via Investor's Business Daily · March 19, 2025
Wednesday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Via Chartmill · March 19, 2025
Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Sleptbenzinga.com
Via Benzinga · March 19, 2025
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Expertsbenzinga.com
Via Benzinga · March 11, 2025
Gilead Sciences's Options: A Look at What the Big Money is Thinkingbenzinga.com
Via Benzinga · March 10, 2025
P/E Ratio Insights for Gilead Sciencesbenzinga.com
Via Benzinga · March 7, 2025
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Yearsbenzinga.com
Via Benzinga · March 6, 2025
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slidesbenzinga.com
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the epidemic.
Via Benzinga · March 19, 2025
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Via StockStory · March 19, 2025
Unpacking the Latest Options Trading Trends in Gilead Sciencesbenzinga.com
Via Benzinga · March 18, 2025
Gilead Sciences - Leader In HIV Medicinestalkmarkets.com
The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.
Via Talk Markets · March 14, 2025
Friday's session: top gainers and losers in the S&P500 indexchartmill.com
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · March 14, 2025
Is Gilead Sciences Gaining or Losing Market Support?benzinga.com
Via Benzinga · March 13, 2025
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why.chartmill.com
A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors.
Via Chartmill · March 13, 2025
Gilead Presents New HIV Treatment And Cure Research Databenzinga.com
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.
Via Benzinga · March 12, 2025
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards a cure.
By Gilead Sciences, Inc. · Via Business Wire · March 12, 2025
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)fool.com
Via The Motley Fool · March 11, 2025
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
As the United States stock market continues to drop, investors are turning their attention to defensive investments. Dividend stocks have always been an investor favorite when prices start to drop, providing immediate income that can potentially offset falling prices in other areas.
Via MarketBeat · March 11, 2025
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The Lancet. Data will support the future development of once-yearly lenacapavir for PrEP, for which Gilead plans to launch a Phase 3 study in the second half of 2025.
By Gilead Sciences, Inc. · Via Business Wire · March 11, 2025
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · March 11, 2025
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).
Via StockStory · March 11, 2025
1 Value Stock with Exciting Potential and 2 to Ignore
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · March 10, 2025
Best And Worst Performing S&P 500 Stocks Since Trump's Election Winbenzinga.com
Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.
Via Benzinga · March 7, 2025
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook.investors.com
Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products.
Via Investor's Business Daily · February 26, 2025